Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | FPR2 | P25090 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173659 | 0.96 | AKR1C3 (0.92) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL3099610 | 0.92 | AKR1C3 (0.85) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13173658 | 0.91 | AKR1C3 (0.83) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13173661 | 0.91 | AKR1C3 (0.83) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13174267 | 0.90 | AKR1C3 (0.81) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13174162 | 0.89 | AKR1C3 (0.80) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13173592 | 0.89 | AKR1C3 (0.80) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13100333 | 0.89 | AKR1C3 (0.80) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL3089436 | 0.89 | AKR1C3 (0.80) | AKR1C3MEN1KMT2AHRH4NPC1 | |
| SCHEMBL13173657 | 0.88 | AKR1C3 (0.79) | AKR1C3MEN1KMT2AHRH4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | claimed |
| EP-2181990-B1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2012-08-08 | — | — | EP | claimed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | claimed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | claimed |
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260035340-A1 | INHIBITORS OF AKR1C3 AND METHODS OF USE | UNIV NEBRASKA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3962921-B1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | HEALTH RESEARCH INC (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | RHODE ISLAND HOSPITAL | 2025-09-25 | — | — | US | disclosed |
| EP-4598933-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | Allorion Therapeutics Inc (US) | 2025-08-13 | — | — | EP | disclosed |
| US-12337004-B2 | Coumarin-modified androgens for the treatment of prostate cancer | HEALTH RESEARCH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| CN-119968377-A | Phosphoramidate compounds and uses thereof | 安锐生物医药公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024078392-A1 | PHOSPHORAMIDATE COMPOUNDS AND USES THEREOF | ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD. (CN) | 2024-04-18 | — | — | WO | disclosed |
| EP-2181990-B1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2181990-B1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| WO-2010101127-A1 | INDOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-09-10 | — | — | WO | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115207-A1 | COUMARIN-MODIFIED ANDROGENS FOR THE TREATMENT OF PROSTATE CANCER | AR, KLK3, SHBG | AKR1C3 158/4885MEN1 1789/4885KMT2A 4417/4885 |
| US-12337004-B2 | Coumarin-modified androgens for the treatment of prostate cancer | AR, SHBG, NCOA1 | AKR1C3 90/4885MEN1 1515/4885KMT2A 4466/4885 |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | AR, NR5A1, CYP17A1 | AKR1C3 72/4885MEN1 2482/4885KMT2A 1056/4885 |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | SHBG, AR, HSD17B11 | AKR1C3 230/4885MEN1 3887/4885KMT2A 1777/4885 |
| US-20260035340-A1 | INHIBITORS OF AKR1C3 AND METHODS OF USE | AKR1C3, AKR1C2, AKR1C1 | AKR1C3 1/4885MEN1 3967/4885KMT2A 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.